Cipemastat (rINN also known as Ro 32-3555 and by the tentative trade name Trocade) is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent. It is being developed by Roche.
This page contains content from the copyrighted Wikipedia article "Cipemastat"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.